Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt

Table 1 Basic clinical data

Clinical characteristic	TAF (n = 32)	TDF (n = 35)	ETV (n = 70)	Statistic	P value	Total (n = 137)
Gender, n (%)				X2 = 1.033	0.597
Male	20	18	37			75
Female	12	17	33			52
Age (yr, mean ± SD)	53.8 ± 8.5	54.4 ± 7.3	54.5 ± 10.3	t = 0.234	0.815	54.3 ± 9.2
Child-Pugh classification				X2 = 1.623	0.805
A	9	14	21			44
B	18	17	37			72
C	5	4	12			21
Child-Pugh score	6.94 ± 1.29	7.46 ± 2.14	7.26 + 1.64	F = 1.119	0.330	7.31 ± 1.75
MELD score	10.37 ± 2.94	9.69 ± 2.96	10.41 ± 2.93	F = 0.775	0.463	10.22 ± 2.93
Prothrombin time (s)	14.40 ± 1.86	15.14 ± 2.81	14.95 ± 2.73	F = 0.930	0.354	14.74 ± 2.59
Albumin (g/L)	35.27 ± 5.65	34.14 ± 5.01	34.43 ± 4.33	F = 0.496	0.610	34.55 + 4.82
eGFR (mL/min/1.73 m2)	91.22 ± 10.67	90.37 ± 14.24	90.19 ± 12.05	F = 0.078	0.925	90.47 ± 12.27
Cr (μmol/L)	75.04 ± 36.60	78.07 ± 39.72	71.56 ± 23.70	F = 0.940	0.349	74.04 ± 31.51
Total bilirubin (μmol/L)	36.83 ± 14.74	38.62 ± 17.21	34.10 ± 15.69	F = 0.868	0.387	35.89 ± 15.89
PPG before TIPS (mmHg)	25.41 ± 4.82	25.71 ± 5.49	25.84 ± 5.49	F = 0.073	0.929	25.71 ± 5.31
PPG after TIPS (mmHg)	9.52 ± 2.28	9.97 ± 3.04	10.13 ± 2.81	F = 0.530	0.590	9.95 ± 2.75
Deaths in 24 mo, n (%)	3 (9.4)	4 (11.4)	10 (14.3)	X2 = 0.517	0.772	17 (13.7)
HCC in 24 mo, n (%)	2 (6.3)	2 (5.7)	7 (10)	X2 = 0.712	0.700	11 (9.3)
HE in 24 mo, n (%)	6 (18.8)	8 (22.9)	18 (25.7)	X2 = 0.770	0.681	32 (25.4)

MELD: Model for end-stage liver disease; TIPS: Transjugular intrahepatic portosystemic shunt; PPG: Portal pressure gradient; HE: Hepatic encephalopathy; HCC: Hepatocellular carcinoma; eGFR: Estimated glomerular filtration rate; TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.

Table 2 Child-Pugh constituent ratio

	Baseline	1 mo	3 mo	6 mo	12 mo	24 mo
TAF, n (%)	9/18/5 (32)	4/23/5 (32)	3/23/6 (32)	6/22/4 (32)	7/18/2 (27)	14/8/1 (23)
Child-Pugh A/B/C (%)	28.1/56.3/15.6	12.5/71.9/12.7	12.7/74.6/15.6	18.8/68.8/12.5	25.9/66.7/7.4	60.9/34.8/4.3
TDF(n)	14/17/4 (35)	4/25/6 (35)	4/23/8 (35)	7/21/5 (33)	6/20/3 (29)	7/11/3 (21)
Child-Pugh A/B/C (%)	40.0/48.6/11.4	11.4/71.4/12.0	11.4/65.8/22.8	21.2/63.6/15.2	20.7/68.9/10.4	33.3/52.4/14.3
ETV, n (%)	21/37/12 (70)	9/47/13 (69)	6/47/16 (69)	11/44/11 (66)	11/42/6 (59)	11/24/5 (40)
Child-Pugh A/B/C (%)	30.3/52.9/17.1	13.1/68.1/18.8	8.7/68.1/23.2	16.7/66.6/16.7	18.6/71.2/10.2	27.5/60.0/12.5

TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.